Matthew Memoli

“I wanted to tell young researchers and the scientific community that is absolutely not true that we are at the NIH 100% committed to making sure that early career researchers get the the resources they need for the training that they're having and so that they can become excellent scientists.”

— From Director's Desk: Young Investigative visionaries featuring NIH Deputy Director Matt Memoli, National Institutes of Health (NIH) (June 11, 2025)

“The key thing is to realize is that what we were doing before wasn't working actually what we were doing before despite the the the commitment that the NIH would say to support young scientists nevertheless scientists were taking longer and longer and longer to get to to get to be able to get large grants right and so...”

— From Director's Desk: Young Investigative visionaries featuring NIH Deputy Director Matt Memoli, National Institutes of Health (NIH) (June 11, 2025)

“the most important thing is making sure that your assay is not going to react with other coronaviruses and as soon as you've got that validated assay and you've got the good statistics we can start moving forward and analyzing the samples”

— From EPIDEMIC Podcast / S1E21: Are Antibodies the Holy Grail? / Kaitlyn Sadtler & Matt Memoli, JUST HUMAN PRODUCTIONS (May 19, 2020)

“to me the biggest use for these antibody tests right now is research it's trying to understand the disease understand the immunity learning what the core of protection are so that we can inform better vaccine development design endpoints and so forth so that we can deal not only with this problem but also deal with any...”

— From EPIDEMIC Podcast / S1E21: Are Antibodies the Holy Grail? / Kaitlyn Sadtler & Matt Memoli, JUST HUMAN PRODUCTIONS (May 19, 2020)

“So other than taking care of patients with highly contagious diseases we do special clinical studies. This is primarily what I do here; I run a number of those trials that are done in this unit. Some of those trials are sort of these special trials that we call challenge trials, where we take healthy volunteers who dec...”

— From Tour the Special Clinical Studies Unit with Dr. Matthew Memoli, NIAID (November 01, 2018)

“Developing a new and better influenza vaccine is extraordinarily challenging because the influenza virus is very good at changing. It's very good at adapting and surviving and the virus is constantly changing from year to year, and we also have the threat of new viruses appearing, moving from animals to human, or even...”

— From Tour the Special Clinical Studies Unit with Dr. Matthew Memoli, NIAID (November 01, 2018)